Galectins, a class of unconventional lectins;Les galectines: Des lectines pas comme les autres

Medecine/Sciences

Volumn 31, Issue 5, 2015, Pages 499-505

  Advedissian, Tamara ^a   Deshayes, Frédérique ^a   Poirier, Françoise ^a   Grandjean, Cyrille ^b   Viguier, Mireille ^a  

^a INSTITUT JACQUES MONOD   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; MUS;

GALECTIN; POLYSACCHARIDE;

ADAPTIVE IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BINDING SITE; CELL ADHESION; CELL FRACTIONATION; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CHEMISTRY; DRUG DESIGN; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; INFECTION; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; MOLECULAR EVOLUTION; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIGENE FAMILY; MUTATION; NEOPLASMS; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RNA SPLICING;

ADAPTIVE IMMUNITY; ANIMALS; APOPTOSIS; BINDING SITES; CELL ADHESION; CELL PHYSIOLOGICAL PROCESSES; DRUG DESIGN; EVOLUTION, MOLECULAR; GALECTINS; GENE EXPRESSION REGULATION; HUMANS; INFECTION; INFLAMMATION; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; MULTIGENE FAMILY; MUTATION; NEOPLASMS; POLYSACCHARIDES; PROTEIN STRUCTURE, TERTIARY; RNA SPLICING; SUBCELLULAR FRACTIONS; SUBSTRATE SPECIFICITY;

EID: 84931036410     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20153105011     Document Type: Review

References (39)

1. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994; 76 : 597-8.
2. Leffler H, Carlsson S, Hedlund M, et al. Introduction to galectins. Glycoconj J 2004; 19 : 433-40.
3. Cooper DNW. Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002; 1572 : 209-31.
4. Houzelstein D, Gonçalves IR, Orth A, et al. Lgals6, a 2-million-year-old gene in mice: a case of positive Darwinian selection and presence/absence polymorphism. Genetics 2008; 178 : 1533-45.
5. Wang JL, Gray RM, Haudek KC, Patterson RJ. Nucleocytoplasmic lectins. Biochim Biophys Acta 2004 ; 1673 : 75-93.
6. Rabinovich GA, Toscano MA. Turning sweet on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9 : 338-52.
7. Hirabayashi J, Hashidate T, Arata Y, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572 : 232-54.
8. Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry (Mosc) 1998; 37 : 4086-92.
9. Morris S, Ahmad N, André S, et al. Quaternary solution structures of galectins-1, -3, and -7. Glycobiology 2004; 14 : 293-300.
10. Lepur A, Salomonsson E, Nilsson UJ, Leffler H. Ligand induced galectin-3 protein self-association. J Biol Chem 2012; 287 : 21751-6.
11. Gauthier L, Rossi B, Schiff C. La galectine-1 est un ligand du récepteur des lymphocytes pré-B. Med Sci (Paris) 2003; 19 : 144-6.
12. Elantak L, Espeli M, Boned A, et al. Structural basis for galectin-1-dependent pre-B cell receptor (pre-BCR) activation. J Biol Chem 2012; 287 : 44703-13.
13. nd ed. Cold Spring Harbor (NY) : Cold Spring Harbor Laboratory Press, 2009.
14. Delacour D, Koch A, Jacob R. The role of galectins in protein trafficking. Traffic 2009; 10 : 1405-13.
15. Villeneuve C, Baricault L, Canelle L, et al. Mitochondrial proteomic approach reveals galectin-7 as a novel BCL-2 binding protein in human cells. Mol Biol Cell 2011; 22 : 999-1013.
16. Lakshminarayan R, Wunder C, Becken U, et al. Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers. Nat Cell Biol 2014; 16 : 595-606.
17. Gendronneau G, Sidhu SS, Delacour D, et al. Galectin-7 in the control of epidermal homeostasis after injury. Mol Biol Cell 2008; 19 : 5541-9.
18. Georgiadis V, Stewart HJS, Pollard HJ, et al. Lack of galectin-1 results in defects in myoblast fusion and muscle regeneration. Dev Dyn 2007; 236 : 1014-24.
19. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006; 103 : 15975-80.
20. Boscher C, Zheng YZ, Lakshminarayan R, et al. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem 2012; 287 : 32940-52.
21. Goetz JG, Joshi B, Lajoie P, et al. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol 2008; 180 : 1261-75.
22. Hikita C, Vijayakumar S, Takito J, et al. Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin-3. J Cell Biol 2000; 151 : 1235-46.
23. Gendronneau G, Sanii S, Dang T, et al. Overexpression of galectin-7 in mouse epidermis leads to loss of cell junctions and defective skin repair. PLoS One 2015; 10 : e0119031.
24. Haudek KC, Spronk KJ, Voss PG, et al. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta 2010 ; 1800 : 181-9.
25. Vyakarnam A, Dagher SF, Wang JL, Patterson RJ. Evidence for a role for galectin-1 in pre-mRNA splicing. Mol Cell Biol 1997; 17 : 4730-7.
26. Haudek KC, Patterson RJ, Wang JL. SR proteins and galectins: what's in a name? Glycobiology 2010; 20 : 1199-207.
27. Chen HY, Weng IC, Hong MH, Liu FT. Galectins as bacterial sensors in the host innate response. Curr Opin Microbiol 2014; 17 : 75-81.
28. Stowell SR, Arthur CM, Dias-Baruffi M, et al. Innate immune lectins kill bacteria expressing blood group antigen. Nat Med 2010; 16 : 295-301.
29. Nieminen J, St-Pierre C, Bhaumik P, et al. Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J Immunol 2008; 180 : 2466-73.
30. Hrynchyshyn N, Jourdain P, Desnos M, et al. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis 2013; 106 : 541-6.
31. Harazono Y, Nakajima K, Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev 2014; 33 : 285-94.
32. Newlaczyl AU, Yu LG. Galectin-3: a jack-of-all-trades in cancer. Cancer Lett 2011; 313 : 123-8.
33. Sanchez-Ruderisch H, Fischer C, Detjen KM, et al. Tumor suppressor p16 INK4a: downregulation of galectin-3, an endogenous competitor of the proanoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J 2010; 277 : 3552-63.
34. Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005; 65 : 8350-8.
35. Clark MC, Pang M, Hsu DK, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012; 120 : 4635-44.
36. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172 : 288-98.
37. Klyosov A, Zomer E, Platt D. DAVANAT® (GM-CT-01) and colon cancer: preclinical and clinical (phase I and II) studies. In : Klyosov AA, ed. Glycobiology and drug design, vol. 1102. Washington, DC : American Chemical Society, 2012 : 89-130.
38. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014; 40 : 307-19.
39. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012; 185 : 537-46.